



ALIZÉ PHARMA



One line pitch:

Group of biotech companies specialized in the development of Biopharmaceuticals for Metabolic Diseases and Rare Diseases

Market Analysis:

Alizé Pharma is a group of companies specialized in the development of innovative biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases and rare diseases. The group is managed by a team of drug development experts and a board of directors with a breadth of international experience. Its business strategy is to advance programs based on medical innovation to the clinical stage and establish partnerships with pharmaceutical companies to secure both short and long-term revenue streams. Since its creation in 2007 the group has raised 15,1 M€ from private and institutional investors and has acquired and implemented 3 programs. As of 2015, 2 programs are at the clinical stage and a first industrial partnership has been signed.

Business Proposition:

Alizé Pharma SAS, is developing AZP-531, a stabilized analog of unacylated ghrelin, a physiological gastrointestinal peptide. This program is in Phase II clinical development for the treatment of Prader-Willi syndrome and in Phase Ib for type 2 diabetes. Alizé Pharma II SAS, is focusing on the development of pegcrisantaspase (ASPAREC® / JZP416), a new pegylated recombinant L-asparaginase for the treatment of acute lymphoblastic leukemia (ALL). It is partnered with Jazz Pharmaceuticals (Nasdaq: JAZZ) and is in Phase II/III clinical development. Alizé Pharma III SAS has acquired exclusive worldwide rights on a family of new peptides with bone anabolic properties, to be developed in osteoporosis and other bone diseases. I-HBD1 program is at the lead optimization stage.

Competitive Advantage:

Investment Attractiveness:

- Innovative corporate organization (each asset has its own corporate entity) provides shareholders with return on a project by project basis. - Founded by a team of experienced drug developers, and with experienced management and board - International network of KOLs for the sourcing of projects - Two clinical-stage projects and a first partnership; a third program launched in 2015 - Financing objectives in the next 12-18 months: 5M€ in Alizé Pharma III SAS to launch the I-HBD1 development program (1,8 M€ already raised in 2015 for the lead optimization program)

IP Situation:

Altogether, more than 50 patents and patent applications, filed internationally, covering the products in development (Asparec/JZP416; AZP-531; I-HBD1) and their therapeutic uses.

COMPANY PROFILE

- **Website:**
www.alz-pharma.com
- **Activity:** Biotech
- **Contact:**
ABRIBAT Thierry
tabribat@alz-pharma.com
- **Location:**
15 chemin du Saquin Bldg G
69130 Ecully
France
- **Founded in:** 23/04/2007
- **Employees:** 7
- **Management:**
Abribat Thierry
President
Allas Soraya
Medical Director
- **Financial information (€):**
 - **Company stage:**
Clinical
 - **Capital raised to date:**
15.1 M€
 - **Monthly burn rate:**
 - **Capital seeking and date:**
5 M€ in 2016 (Alizé Pharma III - I-HBD1 program)
- **Investors:**
Innobio (Bpifrance), initiative Octalfa, Sham Innovation Santé, Sofimac Partners, , CEMA, Crédit Agricole Création,, TAB Consulting, Rhone-Alpes Création
- **Referred by:**
Mounia Chaoui